Emma Guttman-Yassky, MD, PhD - Atopic Dermatitis and the 0X40 Pathway: Understanding the Therapeutic Potential of OX40 Inhibition in Atopic Dermatitis
Update: 2025-06-23
Description
Visit https://www.peervoice.com/BAN860 to view the entire programme with slides. After completing “Emma Guttman-Yassky, MD, PhD - Atopic Dermatitis and the 0X40 Pathway: Understanding the Therapeutic Potential of OX40 Inhibition in Atopic Dermatitis”, participants will be able to: Explain the mechanistic rationale for OX40 pathway inhibitors in atopic dermatitis (AD); Describe the benefits and limitations of current disease management strategies in AD; and Use clinical data to evaluate the effects of emerging OX40 inhibitors for patients with AD in the context of current clinical management.
Comments
In Channel